<DOC>
	<DOCNO>NCT00457821</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ivacaftor patient cystic fibrosis ( CF ) age 18 year old G551D mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) gene . Ivacaftor potent selective CFTR potentiator wild-type , G551D , F508del , R117H form human CFTR protein . Potentiators pharmacological agent increase chloride ion transport property channel presence cyclic AMP-dependent protein kinase A ( PKA ) activation .</brief_summary>
	<brief_title>Safety Study Ivacaftor Subjects With Cystic Fibrosis</brief_title>
	<detailed_description>This double-blind , placebo-controlled , cross-over , multiple dose study 28 day dose , subject cystic fibrosis ( CF ) G551D-CTFR gene mutation . Enrollment 39 subject occur 15 center US , Canada , Germany . The study conduct 2 part : - Part 1 consist Group A Group B . Subjects Group A ( 10 subject ) randomize receive 25 mg ivacaftor every 12 hour [ q12h ] ( 4 subject ) , 75 mg ivacaftor q12h ( 4 subject ) , placebo ( 2 subject ) 14 day . Following 7- 28-day washout period , subject receive active study drug cross alternate dose strength ivacaftor additional 14 day . Placebo subject continued receive placebo additional 14 day . Subjects Group B ( 10 subject ) randomize receive 75 mg ivacaftor q12h ( 4 subject ) , 150 mg ivacaftor q12h ( 4 subject ) , placebo ( 2 subject ) 14 day . Following 7- 28-day washout period , subject receive active study drug cross alternate dose strength ivacaftor additional 14 day . Placebo subject continued receive placebo additional 14 day . - Part 2 consist Group C ; subject participate Part 1 . Subjects randomize receive 150 mg ivacaftor q12h ( 7 subject ) , 250 mg ivacaftor q12h ( 7 subject ) , placebo ( 4 subject ) total 28 day . Ivacaftor dose study Part 2 select follow interim pharmacokinetic/pharmacodynamic ( PK/PD ) statistical analysis data Part 1 . The 2 dos select Part 2 anticipate enable good definition optimal therapeutic dose .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Weighing least 40 kg Confirmed diagnosis cystic fibrosis ( CF ) G551D mutation least 1 allele Forced expiratory volume 1 second ( FEV1 ) least 40 % predict normal age , gender , height Willing remain stable medication regimen duration study participation No significant clinical laboratory abnormality , pregnant , willing use least 2 highly effective birth control method Part 1 1 highly effective birth control method Part 2 study No clinically significant abnormality would interfere study assessment , judge investigator History illness condition might confound result study pose additional risk administer study drug subject Ongoing acute respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 14 day Day 1 study History alcohol , medication illicit drug abuse within one year prior Day 1 Abnormal liver function â‰¥ 3x upper limit normal History abnormal renal function ( creatinine clearance &lt; 50 mL/min use CockcroftGault equation ) History solid organ hematological transplantation Pregnant breastfeeding ( woman ) Ongoing participation another therapeutic clinical trial , prior participation investigational drug study without appropriate washout Concomitant use inhibitor inducer cytochrome P450 3A4 ( CYP3A4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>G551D mutation</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Infant , Newborn , Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>